Teva Pharmaceuticals Inc. made more cuts in the United States, this time to real estate holdings. To save money, the company will close its offices in Washington, D.C. and New York City. No jobs were reported to be lost from the cuts.

The U.S. Food and Drug Administration rejected Amgen’s and UCB’s Biologics License Application for Evenity (romosozumab) for postmenopausal women with osteoporosis.

As Radius Health moves forward following the April 2017 approval of osteoporosis drug Tymlos, the company will do so with a new leader at the helm.

The number of new drugs approved for sale in United States and Europe has bounced back in 2017, suggesting a marked slowdown in 2016 was an aberration.

A federal appeals court revived claims by plaintiffs accusing Merck & Co. of failing to adequately warn about risks of thigh bone fractures associated with Fosamax.

Investors and biotech insiders are waiting during March 2017 for the U.S. Food and Drug Administration to rule on six therapies that will impact the bottom line of the developers, according to an analysis by RTT News.

Merck & Co. Inc. said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.

(Reuters Health) – Low levels of exposure to the metal cadmium may increase the risk of weaker bones and fractures in elderly men, a Swedish study suggests. Cadmium is a naturally occurring metal used in batteries and found in cigarette smoke and exhaust from fossil fuels or waste incineration. As a result of crops grown […]

November 18, 2015By Mark Terry, Breaking News Staff   Waltham, Mass.-based Radius Health, Inc. (RDUS), announced yesterday that it has sent a Marketing Authorization Application (MAA) to European regulatory agencies for its abaloparatide-SC for postmenopausal osteoporosis. At the same time, the company indicated that it is delaying its New Drug Application (NDA) to the […]

PHILADELPHIA, Oct. 19, 2015 /PRNewswire/ — TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016. Calcitonin has been available as […]